ArticleBMC cancer2026
Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The cerebrospinal fluid immune microenvironment in lung cancer leptomeningeal metastasis: cellular ecosystems and therapeutic possibilities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLeptomeningeal metastasis (LM) is an almost universally fatal complication of solid tumors. Intrathecal pemetrexed (IP) has preliminary activity; however, robust efficacy and safety data are lacking.
methodsData of 112 patients with newly diagnosed, cytologically and/or radiologically confirmed LM from solid tumors between May 2021 and June 2024 were retrospectively analyzed. All patients received IP as first-line intrathecal therapy. The efficacy and safety of IP were evaluated, and prognostic factors associated with overall survival in the entire cohort and a non-small-cell lung cancer (NSCLC) subgroup were identified.
resultsThe primary tumor types were NSCLC (63.4%), small-cell lung cancer (14.3%), breast cancer (9.8%), and colorectal cancer (5.4%). The median overall survival (mOS) for the entire cohort was 8.0 months (95% confidence interval [CI], 6.5–9.5), with an overall clinical response rate of 75% (84/112). In the NSCLC subgroup, the mOS was 6.0 months (95% CI, 3.6–8.4). Multivariable analysis identified three independent predictors of improved survival: >6 IP administrations (hazard ratio [HR], 0.38; 95% CI, 0.23–0.62; P < 0.001), achievement of a clinical response (HR, 0.53; 95% CI, 0.32–0.88), and negative cerebrospinal fluid cytology after treatment (HR, 0.44; 95% CI, 0.28–0.70; P < 0.001). Importantly, among patients with NSCLC who received > 6 IP cycles, the mOS was 16 months. Treatment-related adverse events were predominantly grades 1–2. The most common symptoms were myelosuppression (41.1%) and elevated hepatic transaminase levels (36.6%).
conclusionsIntrathecal pemetrexed could confer clinically meaningful survival benefits with acceptable toxicity in patients with solid tumor LM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.